Relationships Between Systemic Inflammatory Markers and 18F-FDG PET/CT Imaging and Clinical Findings in Pulmonary Sarcoidosis

• Published in: Curēus (Palo Alto, CA) Vol. 15; no. 3; p. e36521
• Main Authors: Sahin Ozdemirel, Tugce, Akıncı Özyürek, Berna, Tatci, Ebru, Ertan, Ozlem, Akkurt, Esma Sevil, Senturk, Aysegul, Ozmen, Ozlem
• Format: Journal Article
• Language: English
• Published: United States Cureus Inc 22-03-2023; Cureus
• Subjects: Age; Blood tests; Disease; Gender; Hospitals; Inflammation; Lymphatic system; Lymphocytes; Neutrophils; Patients; Pulmonology; Sarcoidosis; Steroids; Tomography; lmr; sii index; sarcoidosis; inflamation; 18f-fdg
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.36521

Background and aim Sarcoidosis is a multisystem inflammatory disease of unknown aetiology. This study aimed to evaluate the relationship between systemic inflammatory parameters, the systemic immune-inflammation index (SII) and the lymphocyte-to-monocyte ratio (LMR), and disease stage, clinical findings, and 18F-fluoro-2-deoxy-D-glucose (18F-FDG) tomography/computed tomography (PET/CT) uptake. Materials and methods Our study included 73 patients. The general characteristics, radiological features, spirometric tests, PET/CT findings, and laboratory parameters of the patients were recorded. Results Relapse and parenchymal fibrosis were not associated with metabolic parameters, such as LMR and SII. Serum angiotensin-converting enzyme (ACE) levels were lower in the relapsed group than in the non-relapse group. However, the patients' PET/CT images indicated that 18F-FDG parenchym maximum standard uptake value (SUV max), lymph node SUV max, lymph node short axis dimension, SII, and LMR were similar between all patients, relapsed or not. Conclusion Although found to be significant in other inflammatory diseases, we found that SII and LMR alone did not indicate disease prognosis in sarcoidosis due to the small number of patients and the lack of homogeneity between the groups in our study. The usefulness of these markers for clinical use should be investigated by studies that include those with extrapulmonary sarcoidosis, and that calculate these markers at the time of disease diagnosis and during the post-treatment period.